HBA selects Novartis' Rigby for Mentor of the Year

Share this article:
HBA selects Novartis' Rigby for Mentor of the Year
HBA selects Novartis' Rigby for Mentor of the Year

Novartis's Kevin Rigby has been selected as the Healthcare Businesswomen's Association's Mentor of the Year.

Andre Wyss, president of Novartis Corporation and Novartis Pharmaceuticals, said Rigby's “intuition, optimism, sense of humor and willingness to provide honest, constructive feedback—combined with his skills as an active listener and strategic thinker—make him a sought-after mentor, counselor and confidante to a broad group of individuals.”

Rigby is VP public affairs at Novartis, responsible for government interactions and corporate participation in public policy at federal and state levels. He supervises Novartis's philanthropic obligations, including programs for the uninsured and underinsured, interactions with elected officials, patient groups, trade associations and non-profit organizations. Rigby is also a chairman of the Healthcare Institute of New Jersey, chair of the New Jersey Workplace Blood Donor Coalition, and board secretary of Choose New Jersey. He also serves as vice chair of the board of the Alliance of Aging Research.

The Honorable Mentor awards recognizes one person each year who demonstrates long-term support for the advancement of women in the healthcare industry and who has a personal dedication to developing, mentoring and promoting women in the industry as well as being supportive of the HBA's goals. Rigby will be formally recognized in New York City at the group's 24th annual awards event on Thursday, May 9, 2013.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...